Combination of Crizotinib and Osimertinib in T790M+EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

被引：6
|
作者：
Blasi, Miriam [1 ]
Kazdal, Daniel [2 ,3 ]
Thomas, Michael [1 ,3 ]
Christopoulos, Petros [1 ,3 ]
Kriegsmann, Mark [2 ,3 ]
Brandt, Regine [2 ]
Volckmar, Anna-Lena [2 ]
Kirchner, Martina [2 ]
Heussel, Claus Peter [3 ,4 ]
Stenzinger, Albrecht [2 ,3 ]
Kuon, Jonas [1 ,3 ]
机构：
[1] Heidelberg Univ, Dept Thorac Oncol, Thoraxklin, Rontgenstr 1, DE-69126 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] German Ctr Lung Res DZL, Translat Lung Res Ctr TLRC Heidelberg, Heidelberg, Germany
[4] Heidelberg Univ, Thoraxklin, Diagnost & Intervent Radiol Nucl Med, Heidelberg, Germany
来源：
CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 01期
关键词：
Non-small cell lung cancer; EGFR mutation; MET amplification; Targeted therapy; RESISTANCE; PATIENT; INHIBITORS; GEFITINIB; MECHANISM; AZD9291;
D O I：
10.1159/000513904
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as MET oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile.
引用
收藏
页码：477 / 482
页数：6
相关论文
共 50 条
  • [31] Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment
    Su, Po-Lan
    Tsai, Jeng-Shiuan
    Yang, Szu-Chun
    Wu, Yi-Lin
    Tseng, Yau-Lin
    Chang, Chao-Chun
    Yen, Yi-Ting
    Lin, Chia-Ying
    Lin, Chien-Chung
    Wang, Chin-Chou
    Lin, Meng-Chih
    Su, Wu-Chou
    LUNG CANCER, 2021, 158 : 137 - 145
  • [32] Osimertinib as Salvage Therapy in Advanced Non-Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report
    Tang, Yongtong
    Xu, Jilan
    Chen, Qingle
    Lu, Jianping
    Ren, Li
    Lan, Taihe
    Liao, Taihua
    Chen, Xiaoling
    Yi, Hui
    Zhang, Jun
    Huang, Jie
    CLINICAL CASE REPORTS, 2025, 13 (02):
  • [33] OSIMERTINIB, A THIRD-GENERATION TYROSINE KINASE INHIBITOR TARGETING NON-SMALL CELL LUNG CANCER WITH EGFR T790M MUTATIONS
    McCoach, C. E.
    Jimeno, A.
    DRUGS OF TODAY, 2016, 52 (10) : 561 - 568
  • [34] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Filipits, Martin
    TARGETED ONCOLOGY, 2021, 16 (01) : 77 - 84
  • [35] Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
    Peng, Da
    Shan, Dongfeng
    Dai, Chengcheng
    Li, Jie
    Wang, Zifan
    Huang, Ziyi
    Peng, Rui
    Zhao, Peng
    Ma, Xuezhen
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2033 - 2039
  • [36] The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
    Zhao, Zhe
    Li, Lu
    Wang, Zhijie
    Duan, Jianchun
    Bai, Hua
    Wang, Jie
    JOURNAL OF CANCER, 2020, 11 (11): : 3106 - 3113
  • [37] Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
    Kazmierczak, Dominika
    Eide, Inger Johanne Zwicky
    Gencheva, Radosveta
    Lai, Yi
    Lewensohn, Rolf
    Tsakonas, Georgios
    Grundberg, Oscar
    de Petris, Luigi
    McGowan, Marc
    Brustugun, Odd Terje
    Ekman, Simon
    Hydbring, Per
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 722 - +
  • [38] Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation
    Miyashita, Yosuke
    Ko, Ryo
    Shimada, Naoko
    Mitsuishi, Yoichiro
    Miura, Keita
    Matsumoto, Naohisa
    Asao, Tetsuhiko
    Shukuya, Takehito
    Shibayama, Rina
    Koyama, Ryo
    Takahashi, Kazuhisa
    THORACIC CANCER, 2021, 12 (03) : 329 - 338
  • [39] Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib
    Hui, Jia-Jun
    Ding, Sheng-Jun
    Qin, Bao-Dong
    Ding, Ning
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [40] A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study
    Tang, Xin
    Li, Yuan
    Qian, Wen-lei
    Yan, Wei-feng
    Pang, Tong
    Gong, You-ling
    Yang, Zhi-gang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (09) : 2475 - 2486
12345